BR112014031424A2 - tratamento de células pluripotentes - Google Patents

tratamento de células pluripotentes

Info

Publication number
BR112014031424A2
BR112014031424A2 BR112014031424A BR112014031424A BR112014031424A2 BR 112014031424 A2 BR112014031424 A2 BR 112014031424A2 BR 112014031424 A BR112014031424 A BR 112014031424A BR 112014031424 A BR112014031424 A BR 112014031424A BR 112014031424 A2 BR112014031424 A2 BR 112014031424A2
Authority
BR
Brazil
Prior art keywords
pluripotent cell
pluripotent cells
cell treatment
treating
treatment
Prior art date
Application number
BR112014031424A
Other languages
English (en)
Inventor
Davis Janet
Liu Jiajian
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112014031424A2 publication Critical patent/BR112014031424A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Abstract

resumo patente de invenção: "tratamento de células pluripotentes". a presente invenção refere-se a métodos para tratar células pluripotentes, através do qual as células pluripotentes podem ser eficientemente expandidas em cultura e diferenciadas pelo tratamento de células pluripotentes com um inibidor de atividade da enzima gsk-3b.
BR112014031424A 2012-06-14 2013-06-13 tratamento de células pluripotentes BR112014031424A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261741776P 2012-06-14 2012-06-14
PCT/US2013/045617 WO2013192005A2 (en) 2012-06-14 2013-06-13 Differentiation of human embryonic stem cells into pancreatic endocrine cells

Publications (1)

Publication Number Publication Date
BR112014031424A2 true BR112014031424A2 (pt) 2017-06-27

Family

ID=49756254

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014031424A BR112014031424A2 (pt) 2012-06-14 2013-06-13 tratamento de células pluripotentes

Country Status (14)

Country Link
US (1) US20130337564A1 (pt)
EP (1) EP2861723A4 (pt)
JP (1) JP2015519085A (pt)
KR (1) KR20150030709A (pt)
CN (1) CN104603262A (pt)
AR (1) AR091457A1 (pt)
BR (1) BR112014031424A2 (pt)
CA (1) CA2876671A1 (pt)
MX (1) MX2014015419A (pt)
PH (1) PH12014502748A1 (pt)
RU (1) RU2015100900A (pt)
SG (1) SG11201408150UA (pt)
WO (1) WO2013192005A2 (pt)
ZA (1) ZA201500224B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034922B1 (ru) 2013-03-15 2020-04-07 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
RU2016100219A (ru) 2013-06-11 2017-07-17 Президент Энд Феллоус Оф Гарвард Колледж КЛЕТКИ SC-β И КОМПОЗИЦИИ, И СПОСОБЫ ДЛЯ ИХ СОЗДАНИЯ
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2016100898A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof
WO2016100930A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Methods for generating stem cell-derived b cells and methods of use thereof
EP3234110B1 (en) 2014-12-18 2024-02-28 President and Fellows of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED ß CELLS AND USES THEREOF
US20190359941A1 (en) * 2016-08-18 2019-11-28 National University Of Singapore Substituted azole derivatives for generation, proliferation and differentiation of hematopoietic stem and progenitor cells
KR102516844B1 (ko) * 2016-11-16 2023-04-04 시나타 세라퓨틱스 엘티디 만능성 줄기 세포 분석
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US11433148B2 (en) 2017-05-05 2022-09-06 Centre For Probe Development And Commercialization IGF-1R monoclonal antibodies and uses thereof
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
EA201992595A1 (ru) 2017-05-05 2020-04-21 Фьюжн Фармасьютикалс Инк. Усиление фармакокинетики бифункциональных хелатов и их применения
KR101966523B1 (ko) * 2017-05-29 2019-04-05 차의과학대학교 산학협력단 오가노이드 배양을 위한 조성물 및 방법
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
WO2019099725A1 (en) 2017-11-15 2019-05-23 Semma Therapeutics, Inc. Islet cell manufacturing compositions and methods of use
JP2021526806A (ja) * 2018-06-08 2021-10-11 ノバルティス アーゲー 薬物製品の効力を測定するための細胞ベースアッセイ
WO2020033879A1 (en) 2018-08-10 2020-02-13 Semma Therapeutics, Inc. Stem cell derived islet differentiation
US20200080107A1 (en) 2018-09-07 2020-03-12 Crispr Therapeutics Ag Universal donor cells
JP2022547505A (ja) 2019-09-05 2022-11-14 クリスパー セラピューティクス アクチェンゲゼルシャフト ユニバーサルドナー細胞
CN114364791A (zh) 2019-09-05 2022-04-15 克里斯珀医疗股份公司 通用供体细胞
EP4271796A1 (en) 2020-12-31 2023-11-08 CRISPR Therapeutics AG Universal donor cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060030042A1 (en) * 2003-12-19 2006-02-09 Ali Brivanlou Maintenance of embryonic stem cells by the GSK-3 inhibitor 6-bromoindirubin-3'-oxime
WO2007030870A1 (en) * 2005-09-12 2007-03-22 Es Cell International Pte Ltd Cardiomyocyte production
US8741643B2 (en) * 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US8623648B2 (en) * 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US7939322B2 (en) * 2008-04-24 2011-05-10 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm

Also Published As

Publication number Publication date
EP2861723A2 (en) 2015-04-22
PH12014502748A1 (en) 2015-02-02
SG11201408150UA (en) 2015-01-29
MX2014015419A (es) 2015-07-14
ZA201500224B (en) 2017-09-27
RU2015100900A (ru) 2016-08-10
CN104603262A (zh) 2015-05-06
CA2876671A1 (en) 2013-12-27
WO2013192005A2 (en) 2013-12-27
AR091457A1 (es) 2015-02-04
KR20150030709A (ko) 2015-03-20
JP2015519085A (ja) 2015-07-09
WO2013192005A3 (en) 2014-03-13
US20130337564A1 (en) 2013-12-19
EP2861723A4 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
BR112014031424A2 (pt) tratamento de células pluripotentes
PH12014502258A1 (en) Treatment of pluripotent cells
PH12018501293A1 (en) Differentiation of human embryonic stem cells into pancreatic endocrine cells
GB2555728A (en) Cancer cell enrichment system
UA118248C2 (uk) Інгібітори глюкозилцерамідсинтази
IN2014MN00989A (pt)
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
SG196784A1 (en) Stem cell cultures
IN2015DN00934A (pt)
BR112014027783A2 (pt) diferenciação de células-tronco embrionárias humanas em endoderma pancreático
TW201611843A (en) Methods of treatment with arginine deiminase
EA201490945A1 (ru) Набор, содержащий заменитель сыворотки и лабильные факторы
SG10201804952QA (en) Glucosylceramide synthase inhibitors
MX2015008436A (es) Composiciones para permeabilizar celulas sanguineos fijos y sus usos.
IN2015DN03093A (pt)
MX2016004616A (es) Parches de células musculares y usos de los mismos.
EA201590088A1 (ru) Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета
BR112015020667A2 (pt) método de preparar inibidores de glucosilceramida sintase
BR112016006321A2 (pt) enzima engenheirada tendo atividade aceto acetil-coa hidrolase, micro-organismos compreendendo a mesma, e processos de uso da mesma
SG195170A1 (en) Methods of treating or preventing rheumatic disease
WO2015040497A3 (en) Methods for nuclear reprogramming of cells
WO2011129607A8 (en) Method for increasing stem cell activity and stem cells produced thereby
GB2495059A (en) Mammalian model for amplification of cancer stem cells
MX2013008103A (es) Purificacion de inhibidor de proteasa alfa1 derivado de cultivo celular.
AR087586A1 (es) Sistema enzimatico

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]